The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
The investment will accelerate the overall Sarclisa development program
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Acute therapies continue to report strong growth compared to chronic ones.
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Subscribe To Our Newsletter & Stay Updated
